Critics of President Trump’s international drug price model are using an unconventional attack method against a Republican administration: comparing its policies to socialism.
The policy under fire would peg Medicare payments for specialty drugs closer to the often lower prices other countries pay for the same drugs. The public comment window on this pricing model recently closed, and now Trump’s health regulators are sorting through public and corporate feedback before making their next move.
The pharmaceutical industry has compared the proposal to “socialized health care systems” or “foreign price controls” that would hinder innovation and patient access. Doctors’ groups ...